Variables | Survivor group | Deceased group | Total | Â | Univariate logistic regression analysis | ||
---|---|---|---|---|---|---|---|
 | n = 47 (%) | n = 12 (%) | n = 59 | p value | OR | 95 % CI | p value |
Mean age (years ± SD) | 53.5 ± 17.8 | 69.2 ± 15.6 | 56.7 ± 18.4 |  |  |  |  |
Age > 55 years | 32 (68.1) | 10 (83.3) | 43 | 0.019 | 1.07 | 1.013-1.146 | 0.019 |
Gender – male | 18 (38.3) | 2 (16.7) | 20 | 0.182 |  |  |  |
Patient delay | 28 (59.6) | 10 (83.3) | 38 | 0.012 | 1.87 | 1.274-11.230 | 0.015 |
Patient delay (days), median (range) | 10 (1–124) | 9 (1–91) | 10 (1–124) | 0.389 |  |  |  |
Delay by the doctor in administering AFA | 32 (68.1) | 4 (33.3) | 36 | 0.235 | Â | Â | Â |
Delay by the doctor in administering AFA (days), median (range) | 6 (1–180) | 4 (1–28) | 6 (1–180) | 0.485 |  |  |  |
Prolonged delay by the doctor in administering AFA therapy (>6Â days) | 16 (34.0) | 7 (58.3) | 23 | 0.009 | 1.45 | 1.080-12.070 | 0.008 |
Delay by the doctor in administering corticosteroid | 18 (38.3) | 5 (41.7) | 23 | 0.062 | Â | Â | Â |
Delay by the doctor in administering corticosteroid (days), median (range) | 8 (1–14) | 9 (1–28) | 8 (1–28) | 0.389 |  |  |  |
Total delay | 32 (68.1) | 10 (83.3) | 42 | 0.055 | Â | Â | Â |
Total delay (days), median (range) | 19 (1–180) | 17 (1–91) | 19 (1–180) | 0.459 |  |  |  |
Prior cryptococcal infection, not related to this episode | 11 (23.4) | 2 (16.7) | 13 | 0.762 | Â | Â | Â |
Length of stay in the ICU (days), median (range) | 5 (1–21) | 8 (1–28) | 5 (1–28) | <0.001 | 4.217 | 1.030-23.025 | 0.034 |
Diagnostic criteria | Â | Â | Â | Â | Â | Â | Â |
Serum CrAg >1:512 | 13 (27.7) | 2 (16.7) | 15 | 0.381 | Â | Â | Â |
CSF CrAg >1:512 | 10 (21.3) | 4 (33.3) | 14 | 0.281 | Â | Â | Â |
Initial CSF WBC count per mm3, median (range) | 9 (0–51) | 20 (0–250) | 106 | 0.056 |  |  |  |
CSF opening pressure > 250 mm H2O | 12 (25.5) | 6 (50.0) | 18 | 0.032 | 2.93 | 1.250-6.880 | 0.013 |
Minimum inhibitory concentration of amphotericin B > 0.5 μg/mL | 1 (2.1) | 0 | 1 | 0.559 |  |  |  |
Minimum inhibitory concentration of FLU >8 μg/mL | 1 (2.1) | 0 | 1 | 0.862 |  |  |  |
On AFA | Â | Â | Â | Â | Â | Â | Â |
Deoxy-AmB or lipid-AmB + 5-FC | 33 (70.2) | 6 (50.0) | 39 | 0.005 | 1 |  |  |
Deoxy-AmB or lipid-AmB + FLU | 10 (21.3) | 4 (33.3) | 14 | – | 3.3 | 1.696-15.642 | 0.133 |
FLU | 2 (4.3) | 4 (33.3) | 6 | – | 16.5 | 2.257-120.639 | 0.006 |
Complications | Â | Â | Â | Â | Â | Â | Â |
Respiratory failure | 29 (61.7) | 12 (100.0) | 41 | <0.001 | 5.217 | 1.030-26.425 | 0.046 |
Hydrocephalus | 20 (42.6) | 9 (75.0) | 29 | 0.117 | Â | Â | Â |
Neurosurgical intervention | 5 (10.6) | 6 (50.0) | 11 | 0.147 | Â | Â | Â |
Hepatitis | 15 (31.9) | 4 (33.3) | 19 | 1 | Â | Â | Â |
Stroke | 4 (8.5) | 2 | 6 | 0.591 | Â | Â | Â |